MAM
Supari Studios creates campaign for Clinique’s popular product, Moisture Surge
MUMBAI: Award-winning agency Supari Studios produced the latest campaign for Clinique for their popular product, ‘Moisture Surge’. The film’s release comes from the latest formulation for this product, which offers 72 hours of moisture to the skin. This key feature of the product was beautifully brought under the spotlight by Sanya Malhotra, star of the box office breakout film, ‘Dangal’.
The film follows Sanya through a typical 72 hours in her life, to show how she juggles her work and social life, especially with her hectic schedule. The moisturiser presents itself as the perfect companion and hero that keeps up with her. To ensure the hectic pace of her life is encapsulated, and lend a certain intimacy, the Supari team went with a hand-held style to operate the camera. Similarly, the pacing of the music is quick, which adds to the mood of the film. The film also gives a sneak peek into the lighter moods in Sanya’s life like catching up with her friends, dance practice and how she emerges from it, radiant as ever. The settings take you on a journey with Sanya to give you glimpses of what goes on in her life. The film is meant to speak to the urban, independent and contemporary women of today who go through as much as Sanya does in 72 hours.
Anna Joseph, Director of the film said, “The brief we received was that the film had to cover different moments over 72 hours in Sanya Malhotra’s life. As a young actress her days are filled with all sorts of activities – from photo shoots to rigorous dance rehearsals to downtime with friends – we wanted to give the viewer an insight into her personality as well as establish how Moisture Surge is a product she relies on to keep her skin looking great through the day. We tried to intersperse the product shots organically through the film so they felt like a part of her regular routine. We kept the camera movement fluid and made her interact with the camera as much as possible so it would feel like you’re moving with her through different parts of her day. Lastly, we made sure to put her essence into the film so that it felt natural and fun. She’s a great dancer and a very positive, happy person – it was important to bring that out in the film. “
Supari Studios, Executive Producer, Mitali Sharma said, “When Clinique came to us with the brief for this project, we knew that the 72 hour factor of the product would be pivotal. There’s so much that happens in 72 hours of any person’s life especially someone like Sanya, so this film is extremely relatable for anyone that watches it. When developing the narrative and script for this we felt that the mood and theme of this film would resonate with the target audience “
Brands
Sun Pharma to acquire Organon in $11.75 billion deal at $14 per share
Acquisition to create $12.4 billion pharma giant with global scale and biosimilars push
MUMBAI: Sun Pharmaceutical Industries Limited has signed a definitive agreement to acquire Organon & Co. in an all-cash deal valued at $11.75 billion, marking one of the largest cross-border pharma acquisitions by an Indian firm.
Under the terms of the agreement, Organon shareholders will receive $14.00 per share in cash, with Sun Pharma set to acquire 100 per cent of the company’s outstanding shares. The transaction, approved by the boards of both companies, is expected to close in early 2027, subject to regulatory approvals and shareholder consent.
The deal significantly expands Sun Pharma’s global footprint and strengthens its position across women’s health, biosimilars, and branded generics. The combined entity is projected to generate revenues of around $12.4 billion, placing it among the top 25 pharmaceutical companies globally.
Organon, which was spun off from Merck in 2021, brings a portfolio of over 70 products spanning women’s health and general medicines, with operations across more than 140 countries. Its established presence in key markets such as the US, Europe, and China complements Sun Pharma’s existing strengths and growth ambitions.
Sun Pharmaceutical Industries Limited executive chairman Dilip Shanghvi said, “This transaction represents a significant opportunity for Sun Pharma to build on its vision of reaching people and touching lives. Organon’s portfolio, capabilities and global reach are highly complementary to our own.”
Sun Pharmaceutical Industries Limited managing director Kirti Ganorkar added, “This transaction is a logical next step in strengthening Sun Pharma’s global business. Together, we will become a partner of choice for acquiring and launching new products.”
From Organon’s side, Organon & Co. executive chair Carrie Cox noted, “This all-cash transaction offers compelling and immediate value to Organon stockholders, while positioning the business for continued growth under Sun Pharma.”
Strategically, the acquisition gives Sun Pharma entry into the global biosimilars space as a top 10 player and strengthens its innovative medicines portfolio, which is expected to contribute around 27 per cent of combined revenues. The deal is also expected to nearly double EBITDA and cash flow, supporting long-term deleveraging and investment capacity.
Sun Pharma plans to fund the acquisition through a mix of internal accruals and committed financing from global banks, while maintaining focus on disciplined integration and operational continuity post-merger.
If completed as planned, the deal signals a clear shift in India’s pharmaceutical ambitions, from scale at home to leadership on the global stage, with Sun Pharma positioning itself as a more diversified and innovation-led healthcare powerhouse.
